Gout Drugs When Kidneys Are Impaired
Gout drugs are harder to use when kidney function is reduced, and that is precisely when gout tends to be at its worst. Reduced filtration raises serum urate, so chronic kidney disease makes gout more likely and more severe; at the same time it narrows what can safely be prescribed for it. The result is that gout in kidney disease is frequently under-treated — and under-treatment, rather than the drugs, is usually the bigger risk.
Why kidney disease and gout feed each other
Roughly two-thirds of the body’s daily urate disposal happens through the kidneys, with about a third handled in the gut via the ABCG2 transporter. When the glomerular filtration rate falls, that two-thirds pathway loses capacity and the serum level drifts up. Hyperuricaemia is common across stages 3 to 5 of chronic kidney disease, and clinical gout far more prevalent than in people with normal function.
Several other things pile on. Diuretics are frequently prescribed in kidney disease and heart failure, and they raise urate — the mechanism is covered in our piece on diuretics as a hidden cause of gout. Ciclosporin and tacrolimus, used after transplantation, raise it steeply. Low-dose aspirin nudges it up too. So the person whose kidneys are already struggling often carries two or three extra urate-raising influences.
The attack medicines: where the problem bites first
Treating an acute flare is where reduced kidney function hurts most, because the usual options shrink quickly.
| Drug | In reduced kidney function |
|---|---|
| NSAIDs (naproxen, ibuprofen, indometacin) | Generally avoided below moderate function — they reduce renal blood flow and can precipitate a further drop |
| Colchicine | Cleared partly by the kidney; requires dose reduction and carries a real toxicity risk, especially with interacting drugs |
| Oral steroids | Usually the most workable option; no renal dose adjustment, but affects blood glucose |
| Steroid injection into the joint | Attractive for a single joint; keeps systemic exposure low |
Colchicine deserves particular care. It is eliminated by the kidneys and the liver, and its toxic dose is uncomfortably close to its therapeutic one. In someone with impaired clearance who also takes a drug that blocks colchicine’s metabolism — clarithromycin, some antifungals, verapamil, diltiazem, ciclosporin — levels can climb dangerously, causing diarrhoea and vomiting first and, rarely, marrow suppression and muscle damage. That is not a reason to refuse colchicine; it is a reason for the dose to be set by a prescriber holding your recent kidney numbers and your full medicine list. Our guide to colchicine dose and timing explains why modern regimens are much lower than the older ones.
Allopurinol: used, but started low and titrated carefully
Allopurinol is still the first-choice urate-lowering drug in chronic kidney disease. What changed over the last fifteen years is how it is used. Older practice capped the dose by creatinine clearance, on the theory that this prevented hypersensitivity reactions. That left many people on a dose that never brought urate near target, so they kept flaring and kept accumulating crystals.
Current guidance is different: start at a low dose — lower in kidney impairment than in normal function — and increase gradually while checking serum urate, aiming for the same target as everyone else, below 6 mg/dL (360 µmol/L), or below 5 mg/dL (300 µmol/L) if tophi are present. Doses above the old ceilings are acceptable when reached by slow escalation with monitoring. The starting-low part matters because a low start appears to reduce the risk of the severe hypersensitivity syndrome that reduced kidney function makes more likely; that risk, and the HLA-B*58:01 testing that applies to some ancestries, is set out in our honest look at allopurinol side effects.
The number to ask for: if you have kidney disease and gout, ask what your most recent serum urate was and what the plan is for getting it to target. A prescription alone is not treatment — a dose that never reaches the urate target leaves the crystals where they are.
Febuxostat and the uricosurics
Febuxostat is cleared mainly by the liver, which makes it useful when kidney function is poor and allopurinol is not tolerated or not working. It is generally not first choice, largely because of the cardiovascular signal from the CARES trial; the trade-offs are laid out in allopurinol versus febuxostat.
The uricosuric drugs are the clearest casualty of kidney impairment. Probenecid works by blocking urate reabsorption in the renal tubule, so it depends on filtration that is still happening. As the filtration rate falls, its effect fades, and below moderate impairment it is largely ineffective. This is why the options genuinely narrow rather than merely shift around.
- Allopurinol — first choice; low start, slow titration, urate checked along the way.
- Febuxostat — an option when allopurinol fails or is not tolerated, weighed against cardiovascular history.
- Probenecid — loses effectiveness as filtration falls; rarely the answer in established kidney disease.
- Pegloticase — reserved for severe, treatment-refractory tophaceous gout, given by infusion in specialist care.
Why under-treatment is the thing to push back on
Put the pieces together and you can see how the under-treatment happens. Flares are harder to treat, so they get less effective treatment. The urate-lowering drug is started cautiously and then, often, never increased — because the follow-up blood test does not get done, or because a mild bump in creatinine gets blamed on the allopurinol, or simply because nobody owns the titration. Meanwhile crystals keep depositing. Over years that produces tophi, erosion and disability — the pattern described in what happens if gout goes untreated.
The reasonable thing to raise at a review is not a request for a particular drug. It is the question of whether your serum urate is at target and, if not, what the next step in the plan is. Bring the number if you have it. If your kidney function is the reason for caution, that is a legitimate discussion — but caution should mean careful titration and monitoring, not a dose left permanently at the starting level.
What does not help
- Advice to stop a diuretic or blood pressure drug on your own. Those drugs are treating something, and the swap — if there is a sensible one — is the prescriber’s call.
- Any suggestion that gout in kidney disease is untreatable and must simply be endured. It is harder, not impossible.
- Supplements as a substitute for treatment; the urate effect is small, and some matter more in kidney disease than people expect.
One safety point applies regardless of kidney function: a hot, swollen joint with fever, chills or feeling generally unwell may be a joint infection rather than gout, and that needs same-day medical assessment. Septic arthritis damages a joint fast and is more common in people with multiple health problems.
Frequently Asked Questions
Will treating my gout protect my kidneys?
Probably not, on current evidence. Two large randomised trials of allopurinol in chronic kidney disease found no meaningful slowing of kidney decline. Urate-lowering therapy is prescribed to control gout — to stop flares and dissolve deposits — and that is reason enough. Any kidney benefit remains unproven.
My creatinine rose slightly after starting allopurinol. Is the drug damaging my kidneys?
Allopurinol is not a recognised cause of progressive kidney injury, and small fluctuations in creatinine are common for other reasons. It is still worth raising with your prescriber rather than acting on it — they can look at the trend and at everything else you take. Do not stop the medicine on your own.
Can I take ibuprofen for a flare if I have stage 3 kidney disease?
That is a question for your prescriber or pharmacist, not one to answer from an article, because it depends on your exact function, your blood pressure and your other medicines. NSAIDs are commonly avoided at that level, which is why steroids often come forward instead.
Does dialysis change anything?
It changes a lot. Dialysis removes urate, so levels can be lower and flares less frequent, and drug handling differs entirely. Gout management on dialysis is specialist territory, coordinated with the renal team.
What to read next
- Gout medications compared
- Allopurinol for gout: a practical guide
- Diuretics and gout: a hidden cause
- What actually raises uric acid
